Article

Phase I study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B

2022-05-10

Abstract excerpt

<h4>ABSTRACT</h4> PTX-COVID19-B mRNA vaccine encodes for SARS-CoV-2 Spike protein G614 variant and lacks the proline-proline (986-987 position) mutation present in other COVID-19 vaccines. This Phase 1 observer-blinded, randomized, placebo-controlled, ascending dose study evaluated the safety, tolerability, and immunogenicity of two doses of PTX-COVID19-B vaccine in healthy seronegative adults. Participants receiv...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0470fa06-bd96-51e6-a281-aaa2d084b33d
DOI: 10.1101/2022.05.06.22274690

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Phase I study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-BDOI 10.1101/2022.05.06.22274690Read

Interim Analysis of a Phase I Randomized Clinical Trial on the Safety and Immunogenicity of the mRNA-1283 SARS-CoV-2 Vaccine in AdultsSemantic proximity Read

Safety, Tolerability, and Immunogenicity of PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine in Healthy Adults: Interim results of an open-label and randomised Phase 1 clinical trialSemantic proximity Read

Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled TrialSemantic proximity Read

First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle VaccineSemantic proximity Read

A Phase1 Results of a Non-Stabilized Spike-Encoding mRNA Vaccine in AdultsSemantic proximity Read

An in-depth investigation of the safety and immunogenicity of an inactivated SARS-CoV-2 vaccineSemantic proximity Read

Safety and immunogenicity of a recombinant DNA COVID-19 vaccine containing the coding regions of the spike and nucleocapsid proteins: Preliminary results from an open-label, phase 1 trial in healthy adults aged 19–55 yearsSemantic proximity Read

The COVID-19 pandemic: viral variants and vaccine efficacySemantic proximity Read

Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-BSemantic proximity Read

Safety, Tolerability, and Immunogenicity of a SARS-CoV-2 Recombinant Spike RBD Protein Vaccine: A Randomised, Double-Blind, Placebo-Controlled, Phase 1-2 Clinical Trial (ABDALA Study)Semantic proximity Read

Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA VaccineSemantic proximity Read

Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 studySemantic proximity Read